Immunomedics Inc IMMU shares are trading higher on Tuesday, after Barclays initiated coverage on the company's stock with an Overweight rating and $40 price target.
Immunomedics is a clinical-stage biopharmaceutical company, based in the U.S. The company develops monoclonal antibody-based products for the targeted treatment of cancer and autoimmune disorders, among others.
Immunomedics shares trading up 3.63% at $6.57 on Tuesday. The stock has a 52-week range between $8.92 and $3.26.
Related Links:
Roche's Faster Coronavirus Test Receives FDA Emergency Use Authorization
Gilead's Remdesivir Granted FDA Emergency Use To Treat COVID-19
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
